RxDoctor Payments DataLook up a doctor →

Marni Martinez

Adult Health · Austin, TXNPI 1669756508

Payments from drug & device makers

$14,442in general payments, 2019–2025

Across 762 payments — averaging $18.95 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$4K
  • Takeda Pharmaceuticals U.S.A., Inc.$1K
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$1K
  • Johnson & Johnson$1K
  • QOL Medical, LLC$797
  • Lilly USA, LLC$766
  • plus $5K from 24 others

What the payments were for

  • Food & beverage$14,31799%
  • Education$1241%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$14,442 in reported general payments places this provider in the 95th percentile of 933 adult health providers in Texas.

See all adult health providers in Texas

Medicare billing

Part B allowed, 2024
$23,572
Medicare patients
207
Services billed
247

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Humira(Cf) PenAdalimumab12$80,579
CreonLipase/Protease/Amylase14$65,371
LinzessLinaclotide49$34,703
XifaxanRifaximin15$32,626
Dexlansoprazole DrDexlansoprazole70$23,333
Mesalamine29$16,195
MovantikNaloxegol Oxalate17$7,612
PlenvuPeg3350/Sod Sul/Nacl/Kcl/Asb/C35$4,730
Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates62$3,784
ClenpiqSod Picosulf/Mag Ox/Citric Ac19$3,239
Pantoprazole Sodium200$2,786
Balsalazide Disodium15$2,394
Esomeprazole Magnesium18$2,047
Colestipol Hcl17$1,614
Omeprazole47$929

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieCreon, Linzess$3,976$100,07463 claims
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan, Plenvu$1,301$37,35650 claims
Redhill Biopharma Inc.Movantik$174$7,61217 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 933 adult health providers in Texas.

Other adult health in Austin

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →